Cingulate Net Income Over Time
| CING Stock | USD 6.49 0.24 3.84% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cingulate Performance and Cingulate Correlation. Cingulate | Build AI portfolio with Cingulate Stock |
Can Biotechnology industry sustain growth momentum? Does Cingulate have expansion opportunities? Factors like these will boost the valuation of Cingulate. Projected growth potential of Cingulate fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cingulate demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Cingulate requires distinguishing between market price and book value, where the latter reflects Cingulate's accounting equity. The concept of intrinsic value - what Cingulate's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cingulate's price substantially above or below its fundamental value.
It's important to distinguish between Cingulate's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cingulate should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cingulate's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Cingulate and related stocks such as Allarity Therapeutics, Lexaria Bioscience Corp, and Lixte Biotechnology Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLR | (81.2 K) | (81.2 K) | (81.2 K) | (81.2 K) | (68.7 K) | (1.1 M) | (3.7 M) | (4.9 M) | (2.3 M) | (14.3 M) | (6.6 M) | (26.6 M) | (16.1 M) | (11.9 M) | (24.5 M) | (22.1 M) | (21 M) |
| LEXX | (508.3 K) | (343.6 K) | (343.6 K) | (1.9 M) | (1.8 M) | (1.2 M) | (1.9 M) | (6.6 M) | (4.1 M) | (3.9 M) | (4 M) | (7.3 M) | (6.7 M) | (5.8 M) | (11.9 M) | (10.7 M) | (10.2 M) |
| LIXT | (32.9 K) | (2.1 M) | (3.6 K) | (1.4 M) | (2.8 M) | (2.9 M) | (2.1 M) | (1.8 M) | (2.1 M) | (2.4 M) | (3.3 M) | (6.7 M) | (6.3 M) | (5.1 M) | (3.6 M) | (3.2 M) | (3.4 M) |
| KAPA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.1 M) | (1.1 M) | (1.8 M) | (2.6 M) | (2.3 M) | (2.5 M) |
| SYBX | (2.9 M) | (2.9 M) | (3.7 M) | (6.4 M) | (15.8 M) | (25 M) | (26.3 M) | (40.4 M) | (48.4 M) | (48.7 M) | (56.5 M) | (58.1 M) | (66.1 M) | (57.3 M) | (23.4 M) | (21 M) | (22.1 M) |
| CASI | (20 K) | (4.6 M) | (14.5 M) | (5.7 M) | (26.2 M) | (7.2 M) | (9.5 M) | (10.8 M) | (27.5 M) | (45.4 M) | (48.3 M) | (36.7 M) | (41 M) | (26.9 M) | (39.3 M) | (35.3 M) | (33.6 M) |
| NCNA | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (5.3 M) | (6 M) | (23.1 M) | (13.8 M) | (21.4 M) | (30.7 M) | (40.5 M) | (32 M) | (27.6 M) | (19 M) | (17.1 M) | (18 M) |
| BCTX | (8.6 K) | (999 K) | (382 K) | (8.9 M) | (3.5 M) | (2.2 M) | (3.2 M) | (5.4 M) | (5.8 M) | (4.9 M) | (17.6 M) | (34.1 M) | (27.3 M) | (6.5 M) | (36.5 M) | (32.8 M) | (31.2 M) |
Cingulate and related stocks such as Allarity Therapeutics, Lexaria Bioscience Corp, and Lixte Biotechnology Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cingulate financial statement analysis. It represents the amount of money remaining after all of Cingulate operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Cingulate | CING |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1901 West 47th |
| Exchange | NASDAQ Exchange |
USD 6.49
Check out Cingulate Performance and Cingulate Correlation. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Cingulate technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.